"id","uuid:ID","versionIdentifier","rationale","instanceType"
"StudyVersion_1","8a6e830c-25bc-4a4d-8b62-6d28331c4080","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
